Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study |
| Type de publication | Journal Article |
| Year of Publication | 2021 |
| Auteurs | Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, Durelli L, Marignier R, Gignoux L, Laplaud D-A, Moreau T, Clavelou P, de Seze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Trojano M, Patti F, Baulieu E-E, Remontet L, El-Etr M, Study POPARTMUS |
| Journal | MULTIPLE SCLEROSIS JOURNAL |
| Volume | 27 |
| Pagination | 1352458520978218 |
| Date Published | AUG |
| Type of Article | Article |
| ISSN | 1352-4585 |
| Mots-clés | estradiol, multiple sclerosis, post-partum, Progesterone, Relapses, Sex hormones |
| Résumé | {Background: Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy. Objective: To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 17-beta-estradiol (E2) versus placebo. Methods: POPARTMUS is a randomized, proof-of-concept trial in women with MS, receiving oral NOMAc 10 mg/day and transdermal estradiol 75 mu g/week, or placebo. Results: Recruitment was stopped prematurely due to slow inclusions (n = 202). No treatment effect was observed on ARR after 12 weeks (sex steroids = 0.90 (0.58-1.39) |
| DOI | 10.1177/1352458520978218 |